Dion Madsen
Angel Investor @ BDC Venture Capital
Vancouver, Canada
Dion Madsen is a Series A investor at BDC Venture Capital in Vancouver focused on Biotechnology and Biopharma. Mr. Dion Madsen serves as Senior Managing Partner at BDC Healthcare Venture. He serves as a Board Member at Xagenic. Dion brings over 15 years of senior management experience as a financial executive and venture investor, most recently as Founder and Managing Director of Physic Ventures, and as Managing Director of Unilever Technology Ventures,Unilever’s North American corporate venture fund. Prior to Unilever, Dion led Chiron Corporation’s investor communications, as Director of Investor Relations, and buit a new strategy for the company’s $500M BioPharma business. Before moving to San Francisco, Dion spent five years as Partner of RBC Capital Partners’ Life Sciences Venture Fund, the first third-party capital fund in RBC Capital Partners’ history. Dion is a founding member of C100, a select group of the top 100 Canadians in the San Francisco Bay area, and has sat on the boards of directors of many venture capital funds and companies in the pharmaceutical and health care industries. He has also held the roles of M&A Advisor, Strategic Consultant and CFO for a biotechnology company. He currently sits on the Board of Directors of Interface Biologics and is a Board observer at Agrisoma Biosciences, Phemi Health Systems and Chromatin. He is also a selection committee member of the San Francisco Canadian Technology Accelerator. Dion is a CFA® charterholder and has a Bachelor of Commerce in Finance and Marketing from the University of Saskatchewan.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Dion Madsen invests in
Stages Dion Madsen invests in
Countries Dion Madsen invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (46%)
- Biopharma 2 (15%)
- Health Care 2 (15%)
- Life Science 2 (15%)
- Therapeutics 2 (15%)
Stage
- Series A 4 (31%)
- Series B 4 (31%)
- Seed 1 (8%)
- Series C 1 (8%)
- Post-IPO Equity 1 (8%)
Country
- Canada 6 (46%)
- United States 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ability biologics develops novel, tailored immune modifying biotherapeutics to address unmet medical requirements in cancer and autoimmune disease patients. | $18M / Seed / Jun 18, 2024 | ||
| Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases.Zymeworks' approach combines proprietary molecular modeling andsimulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.It was founded in 2004 and headquartered in Vancouver, British Columbia. | Post-IPO Equity / Nov 06, 2019 | ||
| The PHEMI Trustworthy Health DataLab is a unique, cloud-based, integrated big data management system that allows healthcare organizations to enhance innovation and generate value from healthcare data by simplifying the ingestion and de-identification of data with NSA/military-grade governance, privacy, and security built-in.Conventionalproducts simply lock down data, PHEMI goes further, solving privacy and security challenges and addressing the urgent need to secure, govern, curate, and control access to privacy-sensitive personal healthcare information (PHI). This improves data sharing and collaboration inside and outside of an enterprise—without compromising the privacy of sensitive information or increasing administrative burden.Built on privacy-by-design principles, the software gives researchers, scientists, and clinicians faster access to more information while ensuring that they only see data on a need-to-know basis. Responsible data sharing and a governance framework facilitate compliance with privacy regulations.PHEMI Trustworthy Health DataLab can scale to any size of organization, is easy to deploy and manage, connects to hundreds of data sources, and integrates with popular data science and business analysis tools.For more information, visit https://www.phemi.com/ and follow us on Twitter @PHEMISystems, Linkedin, Youtube, and Facebook | $2.8M / Venture - Series Unknown / Sep 01, 2018 | ||
| Agrisoma is a research and development driven organization using a unique technology package to enable new product development in agricultural crops. This technology is being used to create new biofuel crops destined to serve the developing bio-energy market.Agrisoma’s core technology is a proprietary method to introduce, express and managenew genes in plants. Rather than randomly inserting the genes into a crop’s genome as is currently done, Agrisoma’s technology relies on engineering the crops genome to contain an “Engineered Trait Loci†(ETL) that can accommodate an appropriate “dose†and “selection†of genes to reprogram the crop’s biosynthetic activity. The ETL technology is particularly suited to introducing the multiple genes required to achieve enhanced production of biofuels. The ETL technology also has applications for gene stacking. The company began operations in 2002 and has focused on the application of its technology into biofuel development since 2004. Agrisoma has achieved critical milestones in the application of its technology in major oilseeds and biomass crops for the production of renewable fuels. | $9.3M / Series C / Mar 12, 2018 | ||
| The PHEMI Trustworthy Health DataLab is a unique, cloud-based, integrated big data management system that allows healthcare organizations to enhance innovation and generate value from healthcare data by simplifying the ingestion and de-identification of data with NSA/military-grade governance, privacy, and security built-in.Conventionalproducts simply lock down data, PHEMI goes further, solving privacy and security challenges and addressing the urgent need to secure, govern, curate, and control access to privacy-sensitive personal healthcare information (PHI). This improves data sharing and collaboration inside and outside of an enterprise—without compromising the privacy of sensitive information or increasing administrative burden.Built on privacy-by-design principles, the software gives researchers, scientists, and clinicians faster access to more information while ensuring that they only see data on a need-to-know basis. Responsible data sharing and a governance framework facilitate compliance with privacy regulations.PHEMI Trustworthy Health DataLab can scale to any size of organization, is easy to deploy and manage, connects to hundreds of data sources, and integrates with popular data science and business analysis tools.For more information, visit https://www.phemi.com/ and follow us on Twitter @PHEMISystems, Linkedin, Youtube, and Facebook | $10M / Series B / Jun 27, 2017 | ||
| Agrisoma is a research and development driven organization using a unique technology package to enable new product development in agricultural crops. This technology is being used to create new biofuel crops destined to serve the developing bio-energy market.Agrisoma’s core technology is a proprietary method to introduce, express and managenew genes in plants. Rather than randomly inserting the genes into a crop’s genome as is currently done, Agrisoma’s technology relies on engineering the crops genome to contain an “Engineered Trait Loci†(ETL) that can accommodate an appropriate “dose†and “selection†of genes to reprogram the crop’s biosynthetic activity. The ETL technology is particularly suited to introducing the multiple genes required to achieve enhanced production of biofuels. The ETL technology also has applications for gene stacking. The company began operations in 2002 and has focused on the application of its technology into biofuel development since 2004. Agrisoma has achieved critical milestones in the application of its technology in major oilseeds and biomass crops for the production of renewable fuels. | $15.4M / Series B / Apr 11, 2017 | ||
| Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases.Zymeworks' approach combines proprietary molecular modeling andsimulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.It was founded in 2004 and headquartered in Vancouver, British Columbia. | $61.5M / Series A / Jan 08, 2016 | ||
| The PHEMI Trustworthy Health DataLab is a unique, cloud-based, integrated big data management system that allows healthcare organizations to enhance innovation and generate value from healthcare data by simplifying the ingestion and de-identification of data with NSA/military-grade governance, privacy, and security built-in.Conventionalproducts simply lock down data, PHEMI goes further, solving privacy and security challenges and addressing the urgent need to secure, govern, curate, and control access to privacy-sensitive personal healthcare information (PHI). This improves data sharing and collaboration inside and outside of an enterprise—without compromising the privacy of sensitive information or increasing administrative burden.Built on privacy-by-design principles, the software gives researchers, scientists, and clinicians faster access to more information while ensuring that they only see data on a need-to-know basis. Responsible data sharing and a governance framework facilitate compliance with privacy regulations.PHEMI Trustworthy Health DataLab can scale to any size of organization, is easy to deploy and manage, connects to hundreds of data sources, and integrates with popular data science and business analysis tools.For more information, visit https://www.phemi.com/ and follow us on Twitter @PHEMISystems, Linkedin, Youtube, and Facebook | $9.3M / Series A / Aug 11, 2015 | ||
| Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation.This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples.We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results. | $11.8M / Series B / Jul 09, 2015 | ||
| Interface Biologics, Inc. (IBI) is a commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Their patent-protected technologies include anti-thrombogenic additives for blood contacting medical devices and polymer enabled combination drug delivery devices.IBI has exclusive Endexo™ technology licensing agreements with AngioDynamics for vascular access catheters and with Fresenius Medical Care for chronic dialysis systems. AngioDynamics’ BioFlo PICCS, Ports and DuraMax Dialysis Catheter with IBI’s Endexo technology have received FDA clearance and are gaining commercial traction. IBI also has a joint venture commercial agreement with Qualimed to develop a drug-coated balloon based on IBI’s Kinesyx™ technology. The company was founded in 2001 and is headquartered in Toronto, Canada at the acclaimed MaRS Innovation Centre. | Series B / Jan 13, 2015 | ||
| See all 13 investments → | |||
Co-Investors
About BDC Venture Capital
BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets. The company helps create and develop strongCanadian businesses through financing, consulting services and securitization, with a focus on small and medium-sized enterprises.BDC Venture Capital has been involved in venture capital since 1975 and has to date invested in more than 400 companies involved in the areas of Life Sciences, Telecommunications, Information Technology and Advanced Technologies.
BDC Venture Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ajay Gopal
Associate Director
|
|||
Matt Stanley
Director, Cleantech Practice
|
|||
Annie Marsolais
Chief Marketing Officer
|
|||
Charles Lespérance
Partner
|
|||
Claude Miron
Managing Partner - Growth Equity Partners
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dion Madsen invest in?
Dion Madsen invests primarily in Biotechnology, Biopharma and Health Care startups, most often at Series A and Series B stage. Most of the 13 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dion Madsen?
Public channels for Dion Madsen include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Dion Madsen last invest?
The most recent investment recorded for Dion Madsen closed in Jun 2024. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
